Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE: Shortened HCV Treatment in Injection Drug Users
NCT01364090Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Jun 2012
- Primary completion
- Jun 2015
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 7
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection, sponsored by The Kirby Institute. Primary endpoint: Treatment Efficacy at 36 weeks. Started Jun 2012; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01364090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01364090.